AI-generated analysis. Always verify with the original filing.
Mineralys Therapeutics, Inc. filed an 8-K on March 9, 2026, disclosing that on March 6, 2026, the FDA notified the Company regarding its NDA for lorundrostat for treating adult patients with hypertension in combination therapy under Item 8.01, with a press release attached as Exhibit 99.1 under Item 9.01 and Item 7.01 information not deemed filed.
Event Type
Disclosure
Voluntary
Variant
8-K
, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabil
. Other Events. On March 6, 2026, the FDA notified the Company that its NDA for lorundrostat for the treatment of adult patients with hypertension in combinatio
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on March 9, 2026 104 Cover Page Interactive Data File (embed